• Nykode Therapeutics will present a trial-in-progress poster on its Phase 2 Abili-T study at the ESMO Congress 2026.
• The presentation will highlight the trial design for Abi-Suva, its lead cancer vaccine.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nykode Therapeutics AS published the original content used to generate this news brief on October 23, 2026, and is solely responsible for the information contained therein.